Vivani Medical, Inc. (NASDAQ:VANI), on Wednesday, released preclinical data for NPM-139, its subdermal semaglutide implant under development for chronic weight management in obese and overweight ...

Vivani Medical, Inc. VANI, on Wednesday, released preclinical data for NPM-139, its subdermal semaglutide implant under development for chronic weight management in obese and overweight individuals.

Implants, also known as progestin subdermal implants, are among the available long-acting and reversible family planning methods for women. (Photo by: Jumalynne Doctolero/PIA-NCR) In celebration of ...

Vivani Medical, an emerging biopharmaceutical company in the metabolic diseases space, is developing subdermal implants that are changed once or twice per year, delivering GLP-1R agonist with no ...

Vivani Medical, Inc. (NASDAQ:VANI), on Wednesday, released preclinical data for NPM-139, its subdermal semaglutide implant under development for chronic weight management in obese and overweight ...

The single-rod, etonogestrel-releasing, subdermal implant (ENG implant) is the most effective, long-acting reversible method of contraception available. The failure rate of the ENG implant is 0.05 ...

NPM-139 treatment resulted in nearly 20% placebo-adjusted weight loss from a single administration with expected once or twice-yearly dosing NPM-139 is a miniature, subdermal implant in ...

Peter Parker’s next cinematic outing is officially titled “Spider-Man: Brand New Day.” The fourquel will begin filming this summer, according to director Destin Daniel Cretton, who announced ...

NPM-139 treatment resulted in nearly 20% placebo-adjusted weight loss from a single administration with expected once or twice-yearly dosing NPM-139 is a miniature, subdermal implant in development ...

Kennedy News and Media A woman says a small but invasive cancerous lump on her breast was only discovered because her “quite big” breast implants were “pushing it forward” towards her skin.

NPM-139, a subdermal implant in development using the company's proprietary NanoPortal technology to deliver semaglutide, the active ingredient in Novo Nordisk's Ozempic/Wegovy. Results from a ...